Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Reference: Ipilimumab / Nivolumab for Non-Clear Cell RCC
Phase 2, multicenter, randomized trial (SUNNIFORECAST) Previously untreated advanced/metastatic non-clear cell RCC Ipilimumab + nivolumab (4 cycles) followed by nivolumab maintenan
New Reference: Neoadjuvant FOLFIRNOX for Pancreatic Cancer
Multicenter, randomized, noncomparative phase 2 trial (PANACHE01 FRENCH08 PRODIGE48) Resectable pancreatic adenocarcinoma patients Neoadjuvant mFOLFIRINOX (4 cycles) vs. neoadjuvan
New Reference: Talquetamab for Relapsed/Refractory Multiple Myeloma
Multicentre, open-label, phase 1–2 study (MonumenTAL-1) Relapsed/refractory multiple myeloma pts with ≥3 prior lines of therapy Talquetamab 0.4 mg/kg weekly or 0.8 mg/kg every
New Reference: SOX for Gastric/GEJ AdenoCa
Open-label, randomized, phase 3 trial (RESOLVE) Patients with cT4a N+ M0 or cT4b Nany M0 gastric or gastro-oesophageal junction adenocarcinoma after D2 gastrectomy Perioperative SO
New Protocol: Brentuximab-Rituximab-Lenalidomide for Large Cell Lymphoma
Phase 3, randomized, double-blind, placebo-controlled trial (ECHELON-3) Relapsed or refractory DLBCL after ≥2 lines of therapy, ineligible for or relapsed after SCT or CAR T-cell
New Indication: Adjuvant Pembrolizumab for Bladder Cancer
Phase 3, open-label, randomized trial (AMBASSADOR) High-risk muscle-invasive urothelial carcinoma after radical surgery Pembrolizumab (200 mg q3w for 1 yr) vs. observation
New Reference: Encorafenib, Cetuximab, Chemotherapy in bRAF Mutant Colorectal Cancer
Phase 3, multicenter, randomized trial (BREAKWATER) Previously untreated BRAF V600E-mutant mCRC encorafenib + cetuximab (EC) +mFOLFOX6 vs. SOC
New Indication: Cabozantinib for Advanced Neuroendocrine Tumors
Phase 3, multicenter, randomized, double-blind trial (CABO-NET) Advanced progressive neuroendocrine tumors (NETs) of the pancreas, lung, or gastrointestinal tract Cabozantinib vs.
New Reference: Zanubrutinib for Treatment-Naive CLL
Phase 3, randomized, open-label trial (SEQUOIA) Treatment-naïve CLL/SLL pts without del(17p) Zanubrutinib 160 mg BID until progression vs. Bendamustine + Rituximab (6 cycles)
